Active 0 6 0 6 B-chronic_disease
atopic 7 13 7 13 I-chronic_disease
dermatitis 14 24 14 24 I-chronic_disease
or 25 27 25 27 O
other 28 33 28 33 O
skin 34 38 34 38 O
disease 39 46 39 46 O
associated 47 57 47 57 O
with 58 62 58 62 O
pruritus 63 71 63 71 B-chronic_disease
during 72 78 72 78 O
the 79 82 79 82 O
time 83 87 83 87 O
of 88 90 88 90 O
the 91 94 91 94 O
study 95 100 95 100 O
, 100 101 100 101 O
which 102 107 102 107 O
require 108 115 108 115 O
treatment 116 125 116 125 O
with 126 130 126 130 O
topical 131 138 131 138 B-treatment
corticosteroids 139 154 139 154 I-treatment

CIU 0 3 155 158 B-clinical_variable
diagnosis 4 13 159 168 I-clinical_variable
> 14 15 169 170 O
3 16 17 171 172 B-lower_bound
months 18 24 173 179 I-lower_bound
( 25 26 180 181 O
by 26 28 181 183 O
history 29 36 184 191 O
) 36 37 191 192 O

Clinical 0 8 193 201 O
history 9 16 202 209 O
of 17 19 210 212 O
CIU 20 23 213 216 B-chronic_disease
at 24 26 217 219 O
the 27 30 220 223 O
time 31 35 224 228 O
of 36 38 229 231 O
screening 39 48 232 241 O
, 48 49 241 242 O
as 50 52 243 245 O
defined 53 60 246 253 O
by 61 63 254 256 O
pruritus 64 72 257 265 B-clinical_variable
and 73 76 266 269 I-clinical_variable
hives 77 82 270 275 I-clinical_variable
for 83 86 276 279 O
> 87 88 280 281 O
3 89 90 282 283 B-lower_bound
days 91 95 284 288 I-lower_bound
in 96 98 289 291 O
a 99 100 292 293 O
7 101 102 294 295 O
- 102 103 295 296 O
day 103 106 296 299 O
period 107 113 300 306 O
for 114 117 307 310 O
> 118 119 311 312 O
6 120 121 313 314 B-lower_bound
consecutive 122 133 315 326 I-lower_bound
weeks 134 139 327 332 I-lower_bound
despite 140 147 333 340 O
treatment 148 157 341 350 B-treatment
with 158 162 351 355 I-treatment
H1 163 165 356 358 I-treatment
antihistamine 166 179 359 372 I-treatment

Clinically 0 10 373 383 O
relevant 11 19 384 392 O
major 20 25 393 398 O
systemic 26 34 399 407 B-chronic_disease
disease 35 42 408 415 I-chronic_disease
( 43 44 416 417 O
making 44 50 417 423 O
interpretation 51 65 424 438 O
of 66 68 439 441 O
the 69 72 442 445 O
study 73 78 446 451 O
results 79 86 452 459 O
difficult 87 96 460 469 O
) 96 97 469 470 O
including 98 107 471 480 O
a 108 109 481 482 O
history 110 117 483 490 O
of 118 120 491 493 O
anaphylaxis 121 132 494 505 B-chronic_disease

Females 0 7 506 513 B-gender
must 8 12 514 518 O
be 13 15 519 521 O
surgically 16 26 522 532 O
sterile 27 34 533 540 O
or 35 37 541 543 O
postmenopausal 38 52 544 558 O
or 53 55 559 561 O
using 56 61 562 567 B-contraception_consent
a 62 63 568 569 I-contraception_consent
highly 64 70 570 576 I-contraception_consent
effective 71 80 577 586 I-contraception_consent
form 81 85 587 591 I-contraception_consent
of 86 88 592 594 I-contraception_consent
birth 89 94 595 600 I-contraception_consent
control 95 102 601 608 I-contraception_consent
throughout 103 113 609 619 O
the 114 117 620 623 O
duration 118 126 624 632 O
of 127 129 633 635 O
the 130 133 636 639 O
study 134 139 640 645 O

Male 0 4 646 650 B-gender

Non 0 3 651 654 B-clinical_variable
- 3 4 654 655 I-clinical_variable
diary 4 9 655 660 I-clinical_variable
based 10 15 661 666 I-clinical_variable
UAS 16 19 667 670 I-clinical_variable
scores 20 26 671 677 I-clinical_variable
â‰¥ 27 28 678 679 O
2 29 30 680 681 B-lower_bound
at 31 33 682 684 O
either 34 40 685 691 O
the 41 44 692 695 O
screening 45 54 696 705 O
visit 55 60 706 711 O
( 61 62 712 713 O
Week 62 66 713 717 O
-3 67 69 718 720 O
) 69 70 720 721 O
, 70 71 721 722 O
at 72 74 723 725 O
the 75 78 726 729 O
run 79 82 730 733 O
- 82 83 733 734 O
in 83 85 734 736 O
visit 86 91 737 742 O
( 92 93 743 744 O
Week 93 97 744 748 O
-2 98 100 749 751 O
) 100 101 751 752 O
, 101 102 752 753 O
or 103 105 754 756 O
on 106 108 757 759 O
Day 109 112 760 763 O
1 113 114 764 765 O

Patients 0 8 766 774 O
may 9 12 775 778 O
not 13 16 779 782 O
take 17 21 783 787 O
H2 22 24 788 790 B-treatment
antihistamines 25 39 791 805 I-treatment
and 40 43 806 809 O
leukotriene 44 55 810 821 B-treatment
receptor 56 64 822 830 I-treatment
antagonists 65 76 831 842 I-treatment
within 77 83 843 849 O
7 84 85 850 851 B-upper_bound
days 86 90 852 856 I-upper_bound
before 91 97 857 863 O
screening 98 107 864 873 O
, 107 108 873 874 O
during 109 115 875 881 O
the 116 119 882 885 O
screening 120 129 886 895 O
, 129 130 895 896 O
run 131 134 897 900 O
- 134 135 900 901 O
in 135 137 901 903 O
, 137 138 903 904 O
or 139 141 905 907 O
treatment 142 151 908 917 O
phases 152 158 918 924 O

Use 0 3 925 928 O
of 4 6 929 931 O
any 7 10 932 935 O
investigational 11 26 936 951 B-treatment
drugs 27 32 952 957 I-treatment
within 33 39 958 964 O
30 40 42 965 967 B-upper_bound
days 43 47 968 972 I-upper_bound
of 48 50 973 975 O
screening 51 60 976 985 O

female 0 6 986 992 B-gender

